Difference between revisions of "Vadimezan (AS-A404)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Warner-admin moved page Vadimezan (ASA-404) to Vadimezan (AS-A404) without leaving a redirect) |
m |
||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
− | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vadimezan NCI Drug Dictionary]: A fused tricyclic | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vadimezan NCI Drug Dictionary]: A fused tricyclic analog of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages. |
+ | |||
+ | ==Diseases for which is was unsuccessful== | ||
+ | *[[Non-small cell lung cancer - historical|Non-small cell lung cancer]] | ||
==Also known as== | ==Also known as== | ||
Line 8: | Line 11: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Vascular disrupting agents]] | [[Category:Vascular disrupting agents]] | ||
+ | |||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
[[Category:Stub]] | [[Category:Stub]] |
Latest revision as of 16:49, 1 October 2023
Mechanism of action
From the NCI Drug Dictionary: A fused tricyclic analog of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.
Diseases for which is was unsuccessful
Also known as
- Code names: AS-1404, AS-A404